Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Transit times depend on the carrier and destination
The investment reflects the company's strategic commitment to scaling operations in response to increasing therapeutic uptake In April 2024, Eli Lilly and Company launched Zepbound (tirzepatide) in several European markets following regulatory approval for obesity management
To stay ahead of this shifting environment, pharma companies should consider the following imperatives: Massive patient drop-off undermines obesity GLP-1 uptake: Despite strong demand, only 10% of obesity patients persist with therapy after one year
They had to take valuable time out of their day to drive to the office, wait in line, and eventually see the doctor
Support the Gut-Brain Axis Your gut and brain communicate constantly through what is known as the gut-brain axis
US$ 21.14
US$ 22.44
US$ 22.63
US$ 24.54
US$ 26.32
US$ 26.70
US$ 26.57
